Richard Grant, MD
General Practice · Rainbow City, ALNPI 1790942571
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Alkermes, Inc. at 42.9% of the total. Reporting peaked in 2023 at $1,743 and has fallen 63.2% since, to $641 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$3K
- Johnson & Johnson$467
- AbbVie$412
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$329
- Teva Pharmaceuticals USA, Inc.$315
- Otsuka America Pharmaceutical, Inc.$268
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,02996%
- Education$2434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 80 | $2,688 |
| Johnson & Johnson | 5 | $467 |
| AbbVie | 17 | $412 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $329 |
| Teva Pharmaceuticals USA, Inc. | 10 | $315 |
| Otsuka America Pharmaceutical, Inc. | 4 | $268 |
| Neurocrine Biosciences, Inc. | 7 | $190 |
| Supernus Pharmaceuticals, Inc. | 9 | $187 |
| Collegium Pharmaceutical, Inc. | 11 | $161 |
| Lundbeck LLC | 9 | $154 |
| Eisai Inc. | 3 | $153 |
| Biodelivery Sciences International, Inc. | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $124 |
| Almatica Pharma LLC | 6 | $119 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Brainsway USA Inc | 1 | $87 |
| Axsome Therapeutics, Inc. | 2 | $80 |
| Indivior Inc. | 3 | $72 |
| Daiichi Sankyo Inc. | 5 | $71 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Neuronetics, Inc. | 2 | $31 |
| Masimo Corporation | 1 | $23 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
| Orexo US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,380
- ARISTADA$1,294
- ARISTADA INITIO$324
- REXULTI$227
- SPRAVATO$226
- Dayvigo$125
- INVEGA SUSTENNA$121
- VRAYLAR$120
- CAPLYTA$116
How this compares
$6,272 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $195,852 |
| Invega SustennaPaliperidone Palmitate | 20 | $34,670 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $25,714 |
| VraylarCariprazine Hcl | 14 | $19,523 |
| Aripiprazole | 111 | $16,879 |
| Paliperidone ErPaliperidone | 32 | $6,709 |
| Atomoxetine Hcl | 33 | $3,406 |
| Clonazepam | 287 | $2,828 |
| Ziprasidone Hcl | 63 | $2,478 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 98 | $2,376 |
| Lurasidone Hcl | 23 | $1,847 |
| Duloxetine Hcl | 240 | $1,826 |
| Quetiapine Fumarate | 223 | $1,715 |
| Oxcarbazepine | 21 | $1,648 |
| Olanzapine | 84 | $1,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $315 | $195,85214 claims |
| Johnson & JohnsonInvega Sustenna | $467 | $34,67020 claims |
| Alkermes, Inc.Lybalvi | $2,688 | $25,71417 claims |
| AbbVieVraylar | $412 | $19,52314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.
Other general practice in Rainbow City
- Frank TombrelloBirmingham$163K
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- John BurgessBirmingham$117K
- Glenn HarnettHoover$113K
- Alan ColemanAthens$30K
- Darrell DoucetteHuntsville$20K
- Earl RogersMobile$19K
- Jennifer DoobrowCullman$16K
- Robert SchusterDadeville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.